OS-2966 是一种人源化的抗 CD29(β1 整合素/ITGB1)中和性单克隆抗体(huIgG1κ),可阻断整合素 β1 信号传导,抑制肿瘤细胞增殖、侵袭、迁移和间充质表型,并增强溶瘤单纯疱疹病毒-1(oHSV)和抗血管生成治疗的疗效,可用于三阴性乳腺癌、高级别脑膜瘤、胶质母细胞瘤以及卵巢癌的相关研究。
OS-2966
产品编号: MS-G01040 纯度: 99.62% 分子量: 145.5 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

OS-2966 是一种人源化的抗 CD29(β1 整合素/ITGB1)中和性单克隆抗体(huIgG1κ),可阻断整合素 β1 信号传导,抑制肿瘤细胞增殖、侵袭、迁移和间充质表型,并增强溶瘤单纯疱疹病毒-1(oHSV)和抗血管生成治疗的疗效,可用于三阴性乳腺癌、高级别脑膜瘤、胶质母细胞瘤以及卵巢癌的相关研究。

生物实验数据

生物活性 OS-2966 is a humanized neutralizing monoclonal antibody against CD29 (β1 integrin/ITGB1) (huIgG1κ) that blocks integrin β1 signaling, inhibits tumor cell proliferation, invasion, migration, and mesenchymal phenotype, and enhances the efficacy of oncolytic herpes simplex virus-1 (oHSV) and anti-angiogenic therapy, and can be used for research on triple-negative breast cancer, high-grade meningioma, glioblastoma, and ovarian cancer.
IC50 & Target

CD29

 

体外研究
(In Vitro)

OS-2966 (20 μg/mL; 0-24 h) 可在 MDA-MB-231 人三阴性乳腺癌腺癌细胞中破坏 c-Met/β1 整合蛋白复合物,使用条件为 20 μg/mL、作用时长最长 24 小时。
OS-2966 (20 μg/mL; 24 h) 可逆转 AP21967 诱导的 MDA-MB-231-iDimerize-c-Met-β1 人三阴性乳腺腺癌细胞中 Snail 和 FOXC2 间质转录因子的上调,可逆转 AP21967 诱导的 MDA-MB-231-iDimerize-c-Met-β1 人三阴性乳腺腺癌细胞的间充质形态变化。
OS-2966 (20 μg/mL; 24 h) 可降低 MDA-MB-231-BO 骨趋向性人三阴性乳腺腺癌细胞中多种间质转录因子 (Snail、FOXC1、FOXC2、Slug、ZEB1、ZEB2) 的表达。
OS-2966 (0.2-100.0 μg/mL; 3 days) 可抑制接种于层粘连蛋白包被塑料上的 NF2 野生型 IOMM-Lee 间变性脑膜瘤细胞的活力,阻断其贴附并诱导细胞变圆。
OS-2966 (50 μg/mL; 3 hours) 可抑制铺层粘连蛋白的塑料培养板上生长的 NF2-野生型间变性脑膜瘤细胞 IOMM-Lee 中 AKT (Ser473) 和 ERK1/2 的磷酸化 (但不抑制 FAK (Tyr397) 的磷酸化),而在未包被的塑料培养板上生长的细胞中未观察到该信号通路的变化。
OS-2966 (感染 oHSV 后 4 小时) 可抑制巨噬细胞向 oHSV 感染及未感染的 LN229 胶质母细胞瘤细胞迁移。
OS-2966 (10 μg/mL; post oHSV treatment, during co-culture with macrophages) 可增强与 RAW264.7 巨噬细胞共培养的 GBM30 原代 GBM 细胞中 oHSV 的复制。
OS-2966 (1-5 mg/mL; 12 h) 可实现针对猪全层耳皮肤的点阵激光消融靶向经皮递送,在有效激光条件下的最大皮肤沉积量为 3.665 μg/cm2,局部皮肤保留率≥70%,同时将透皮渗透降至最低。

Real Time qPCR

Cell Line: MDA-MB-231-iDimerize-c-Met-β1 human triple-negative breast adenocarcinoma cells (engineered to induce c-Met/β1 complex formation with AP21967)
Concentration: 20 μg/mL
Incubation Time: 24 h
Result: Reversed the AP21967-induced upregulation of Snail and FOXC2.

Real Time qPCR

Cell Line: MDA-MB-231-BO bone-seeking human triple-negative breast adenocarcinoma cells
Concentration: 20 μg/mL
Incubation Time: 24 h
Result: Significantly reduced the expression of all assessed mesenchymal transcription factors in MDA-MB-231-BO cells.
Twist expression was not detectable in these cells.

Cell Invasion Assay

Cell Line: MDA-MB-231-iDimerize-c-Met-β1 human triple-negative breast adenocarcinoma cells (engineered to induce c-Met/β1 complex formation with AP21967)
Concentration: 20 μg/mL
Incubation Time: 24 h
Result: Reversed the AP21967-induced increase in invasiveness.

Cell Viability Assay

Cell Line: NF2-deficient MN3 patient-derived anaplastic meningioma sphere cells
Concentration: 6.8, 12.5, 25.0, 50.0, 100.0 μg/mL
Incubation Time: 5 days
Result: Suppressed cell viability by approximately 50% relative to untreated controls.
Showed no apparent dose-response effect across the tested concentrations.

Cell Viability Assay

Cell Line: NF2-wild-type IOMM-Lee anaplastic meningioma cells (on uncoated plastic)
Concentration: 0.2, 0.8, 4.0, 20.0, 100.0 μg/mL
Incubation Time: 4 days
Result: Had no effect on cell viability at any tested concentration.
Maintained relative viability near 100% across all doses.

Cell Viability Assay

Cell Line: NF2-wild-type IOMM-Lee anaplastic meningioma cells (on laminin-coated plastic)
Concentration: 0.2, 0.8, 4.0, 20.0, 100.0 μg/mL (viability assay); 50 μg/mL (morphology assessment)
Incubation Time: 3 days (viability assay); 3 hours (morphology assessment)
Result: Suppressed cell viability at all tested concentrations, with significant reductions relative to untreated controls at each dose.
Blocked cell attachment to laminin at 50 μg/mL after 3 hours of exposure.
Induced cell rounding at 50 μg/mL after 3 hours of exposure.

Western Blot Analysis

Cell Line: NF2-deficient MN3 patient-derived anaplastic meningioma sphere cells
Concentration: 50 μg/mL
Incubation Time: 3 hours
Result: Potently suppressed phosphorylation of FAK at Tyr397.
Suppressed phosphorylation of ERK1/2.
Caused no changes in total FAK, total AKT, or phosphorylation of AKT at Ser473.

Western Blot Analysis

Cell Line: NF2-wild-type IOMM-Lee anaplastic meningioma cells (on uncoated or laminin-coated plastic)
Concentration: 50 μg/mL
Incubation Time: 3 hours
Result: Had no effect on phosphorylation of FAK (Tyr397), AKT (Ser473), or ERK1/2 in cells on uncoated plastic.
Suppressed phosphorylation of AKT (Ser473) and ERK1/2 in cells on laminin-coated plastic.
Had no effect on phosphorylation of FAK (Tyr397) in cells on laminin-coated plastic.
Detected β1 integrin expression in cells across all conditions.

Cell Viability Assay

Cell Line: NF2-deficient MN8 patient-derived anaplastic meningioma cells
Concentration: 12.5, 25.0, 50.0 μg/mL (viability assay); 50 μg/mL (attachment assay)
Incubation Time: 4 days (viability assay); 48 hours (attachment assay)
Result: Suppressed cell viability on both uncoated and laminin-coated plastic.
Enhanced inhibitory effect on viability was observed in cells grown on laminin-coated plastic at each tested concentration.
Inhibited cell attachment to laminin at 50 μg/mL after 48 hours of exposure.
体内研究
(In Vivo)

OS-2966 (20 mg/kg;腹腔注射;每周 2 次;持续 6 周) 可显著延长原位植入患者来源高级别脑膜瘤的小鼠的总生存期,并降低肿瘤细胞增殖水平。
OS-2966 (5 mg/kg;腹腔注射;每周 2 次) 可增强皮下胶质母细胞瘤异种移植物中 oHSV 的复制及抗肿瘤效力,使病毒总通量显著增加并抑制肿瘤生长。
OS-2966 (5 mg/kg;腹腔注射;oHSV 给药前 1 天,之后每周 2 次) 可增强原位三阴性乳腺癌异种移植物中 oHSV 的复制能力与抗肿瘤效力,至第 21 天时肿瘤体积缩小 10.9 倍,应答率达 100%,且 50%的肿瘤完全消退。
OS-2966 (5 mg/kg;瘤内注射;于溶瘤疱疹病毒给药前 2 天开始,随后每周 2 次;持续 1 个月) 可增强溶瘤疱疹病毒在颅内胶质母细胞瘤异种移植模型中的抗肿瘤效力,进而缩小肿瘤体积并提高小鼠存活率。
OS-2966 (10 mg/kg;腹腔注射;每周 2 次,采用 3/4 天交替给药间隔) 单药治疗可显著降低腹腔内接种 ES-2 卵巢癌异种移植物的雌性无胸腺裸鼠 Foxn1nu 的腹水体积。
OS-2966 (1 mg/kg;腹腔注射;每周 2 次;与 1 mg/kg 贝伐珠单抗交替给药) 在抑制未接受过贝伐珠单抗治疗的皮下胶质母细胞瘤生长方面,疗效与标准剂量贝伐珠单抗相当。
OS-2966 (5-30 mg/kg; 静脉注射) 以最高 30 mg/kg 的剂量经全身静脉给予非人灵长类动物后耐受性良好,仅在剂量高于 5 mg/kg 时出现轻微、可逆的血液学及血清生化指标变化。
OS-2966 (1-5 mg/kg;腹腔注射;每周 2 次) 可显著抑制皮下贝伐珠单抗耐药性胶质母细胞瘤的生长,其中 5 mg/kg 剂量可使 56%的受试小鼠实现肿瘤完全消退。
OS-2966 (总剂量 160 μg;瘤内给药;持续递送;28 天) 可诱导对贝伐珠单抗耐药的原位胶质母细胞瘤完全消退,抑制肿瘤侵袭,并引发大量肿瘤细胞凋亡。

Animal Model: SCID (7-8-week-old female; orthotopic subdural implantation of patient-derived MN3 anaplastic meningioma cells)
Dosage: 20 mg/kg (survival study); 20 mg/kg (mechanism-of-action studies)
Administration: i.p.; twice weekly; 6 weeks (survival study); i.p.; two doses over 1 week (mechanism-of-action studies)
Result: Significantly extended overall survival compared to controls.
Showed a significant decrease in Ki-67 labeling index compared to controls, indicating reduced tumor cell proliferation.
Animal Model: Athymic nu/nu (female, 4 weeks old, outbred)
Dosage: 5 mg/kg
Administration: i.p.; twice a week
Result: Increased viral replication to a total flux of 97146.67 compared to 2303.633 for oHSV + control IgG.
Significantly suppressed tumor growth compared to oHSV + control IgG.
Animal Model: Athymic nu/nu (female, 4 weeks old, outbred)
Dosage: 5 mg/kg
Administration: i.p.; 1 day prior to oHSV, then twice a week
Result: Increased viral replication to a total flux of 311398.3 compared to 89636.5 for oHSV + control IgG (p = 0.0495).
Reduced mean tumor volume to 29.6 mm3 compared to 322.16 mm3 for oHSV + control IgG by day 21, representing a 10.9-fold reduction in tumor growth.
Achieved a 100% response rate, with 50% of mice showing complete tumor regression, and 100% of tumors had increased necrosis.
Animal Model: Athymic nu/nu (female, 4 weeks old, outbred)
Dosage: 5 mg/kg
Administration: intratumoral; starting 2 days prior to oHSV, then twice a week; 1 month
Result: Significantly reduced tumor size compared to oHSV + control IgG.
Significantly improved mouse survival compared to either monotherapy.
Animal Model: athymic mice (5- to 8-week-old female; subcutaneous xenograft of bevacizumab-resistant BRG3 human glioblastoma cells)
Dosage: 1 mg/kg; 5 mg/kg
Administration: i.p.; twice weekly
Result: Reduced subcutaneous tumor volume significantly compared with control IgG-treated mice.
Induced complete tumor regression in 56% (5/9) of mice at 5 mg/kg after 8 weeks of treatment.
Induced tumor cell apoptosis detected on histology, whereas no apoptosis was observed in IgG control-treated tumors.
Animal Model: athymic mice (5- to 8-week-old female; orthotopic xenograft of bevacizumab-resistant BRG3 human glioblastoma cells)
Dosage: 160 μg total
Administration: intratumoral; continuous delivery; 28 days
Result: Induced complete tumor regression in all 3 treated mice.
Triggered massive tumor cell apoptosis detected via TUNEL staining.
Inhibited striatal tumor invasion significantly, shown by reduced number of invading cells per section and reduced invasion distance compared with IgG control-treated mice.
Altered the invasive morphology of tumor cells, reducing cellular processes.
Clinical Trial
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 145.5 kDa

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础